Boston Scientific CEO Bullish on Atrial Fibrillation Device
(Reuters) - Boston Scientific Corp expects more hospitals will be able to offer its new atrial fibrillation treatment starting by the end of the third quarter as it paces the product's rollout to give physicians time to learn how to use it, its chief executive said.
The device, called Watchman, was approved by U.S. regulators last month as an alternative to long-term use of blood thinners such as warfarin for patients at high risk of stroke.
"It is a big unmet need. There were many patients waiting for this to be approved in the United States," Boston Scientific CEO Mike Mahoney said Tuesday in an interview after the company reported first-quarter earnings.
Help employers find you! Check out all the jobs and post your resume.
The device, called Watchman, was approved by U.S. regulators last month as an alternative to long-term use of blood thinners such as warfarin for patients at high risk of stroke.
"It is a big unmet need. There were many patients waiting for this to be approved in the United States," Boston Scientific CEO Mike Mahoney said Tuesday in an interview after the company reported first-quarter earnings.
Help employers find you! Check out all the jobs and post your resume.